ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis

NASDAQ:ASND • US04351P1012

228.275 USD
+1.44 (+0.64%)
Last: Feb 19, 2026, 12:30 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall ASND gets a fundamental rating of 4 out of 10. We evaluated ASND against 521 industry peers in the Biotechnology industry. ASND may be in some trouble as it scores bad on both profitability and health. ASND is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ASND has reported negative net income.
  • ASND had a positive operating cash flow in the past year.
  • In the past 5 years ASND always reported negative net income.
  • ASND had negative operating cash flow in 4 of the past 5 years.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200M -400M

1.2 Ratios

  • ASND has a better Return On Assets (-17.51%) than 77.54% of its industry peers.
Industry RankSector Rank
ROA -17.51%
ROE N/A
ROIC N/A
ROA(3y)-35.96%
ROA(5y)-39.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200

1.3 Margins

  • ASND's Gross Margin of 86.82% is amongst the best of the industry. ASND outperforms 89.44% of its industry peers.
  • ASND's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ASND so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.4%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ASND has been increased compared to 1 year ago.
  • Compared to 5 years ago, ASND has more shares outstanding
  • Compared to 1 year ago, ASND has an improved debt to assets ratio.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ASND has an Altman-Z score of 2.10. This is not the best score and indicates that ASND is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASND's Altman-Z score of 2.10 is fine compared to the rest of the industry. ASND outperforms 66.60% of its industry peers.
  • The Debt to FCF ratio of ASND is 19.20, which is on the high side as it means it would take ASND, 19.20 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 19.20, ASND belongs to the best of the industry, outperforming 90.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.2
Altman-Z 2.1
ROIC/WACCN/A
WACC7.04%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.04 indicates that ASND should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.04, ASND is doing worse than 85.41% of the companies in the same industry.
  • ASND has a Quick Ratio of 1.04. This is a bad value and indicates that ASND is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ASND has a worse Quick ratio (0.76) than 87.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 0.76
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • ASND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.62%, which is quite impressive.
  • ASND shows a strong growth in Revenue. In the last year, the Revenue has grown by 98.03%.
  • The Revenue has been growing by 152.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.06%
Revenue 1Y (TTM)98.03%
Revenue growth 3Y141.43%
Revenue growth 5Y152.98%
Sales Q2Q%42.31%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.82% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 35.39% on average over the next years. This is a very strong growth
EPS Next Y199.63%
EPS Next 2Y115.14%
EPS Next 3Y85.77%
EPS Next 5Y53.82%
Revenue Next Year96.48%
Revenue Next 2Y66.71%
Revenue Next 3Y51.54%
Revenue Next 5Y35.39%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 51.31 indicates a quite expensive valuation of ASND.
  • Based on the Price/Forward Earnings ratio, ASND is valued cheaply inside the industry as 90.02% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.16. ASND is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 51.31
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ASND indicates a rather cheap valuation: ASND is cheaper than 90.40% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 256.72
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • ASND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ASND's earnings are expected to grow with 85.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y115.14%
EPS Next 3Y85.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ASND does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (2/19/2026, 12:30:13 PM)

228.275

+1.44 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)04-29
Inst Owners103.76%
Inst Owner Change3.35%
Ins Owners0.76%
Ins Owner ChangeN/A
Market Cap13.81B
Revenue(TTM)720.13M
Net Income(TTM)-228.03M
Analysts88.33
Price Target277.84 (21.71%)
Short Float %4.94%
Short Ratio3.95
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-721.94%
Min EPS beat(2)-1098.26%
Max EPS beat(2)-345.63%
EPS beat(4)1
Avg EPS beat(4)-349.46%
Min EPS beat(4)-1098.26%
Max EPS beat(4)49.75%
EPS beat(8)3
Avg EPS beat(8)-180.72%
EPS beat(12)6
Avg EPS beat(12)-116.14%
EPS beat(16)7
Avg EPS beat(16)-89.38%
Revenue beat(2)0
Avg Revenue beat(2)-1.76%
Min Revenue beat(2)-2.04%
Max Revenue beat(2)-1.48%
Revenue beat(4)2
Avg Revenue beat(4)2.63%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)9.46%
Revenue beat(8)4
Avg Revenue beat(8)-2.24%
Revenue beat(12)7
Avg Revenue beat(12)14.27%
Revenue beat(16)11
Avg Revenue beat(16)18.77%
PT rev (1m)2.43%
PT rev (3m)6.44%
EPS NQ rev (1m)-1361.04%
EPS NQ rev (3m)-137.72%
EPS NY rev (1m)-4.28%
EPS NY rev (3m)-41.01%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)-6.55%
Revenue NY rev (1m)0.52%
Revenue NY rev (3m)-2.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 51.31
P/S 16.19
P/FCF 256.72
P/OCF 216.31
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.47
EYN/A
EPS(NY)4.45
Fwd EY1.95%
FCF(TTM)0.89
FCFY0.39%
OCF(TTM)1.06
OCFY0.46%
SpS14.1
BVpS-3.19
TBVpS-3.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.51%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.82%
FCFM 6.31%
ROA(3y)-35.96%
ROA(5y)-39.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.4%
GM growth 5YN/A
F-Score5
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 19.2
Debt/EBITDA N/A
Cap/Depr 47.95%
Cap/Sales 1.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 0.76
Altman-Z 2.1
F-Score5
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)22.97%
Cap/Depr(5y)61.4%
Cap/Sales(3y)0.83%
Cap/Sales(5y)68.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.06%
EPS Next Y199.63%
EPS Next 2Y115.14%
EPS Next 3Y85.77%
EPS Next 5Y53.82%
Revenue 1Y (TTM)98.03%
Revenue growth 3Y141.43%
Revenue growth 5Y152.98%
Sales Q2Q%42.31%
Revenue Next Year96.48%
Revenue Next 2Y66.71%
Revenue Next 3Y51.54%
Revenue Next 5Y35.39%
EBIT growth 1Y53.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year396.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y117.6%
OCF growth 3YN/A
OCF growth 5YN/A

ASCENDIS PHARMA A/S - ADR / ASND FAQ

Can you provide the ChartMill fundamental rating for ASCENDIS PHARMA A/S - ADR?

ChartMill assigns a fundamental rating of 4 / 10 to ASND.


What is the valuation status for ASND stock?

ChartMill assigns a valuation rating of 4 / 10 to ASCENDIS PHARMA A/S - ADR (ASND). This can be considered as Fairly Valued.


What is the profitability of ASND stock?

ASCENDIS PHARMA A/S - ADR (ASND) has a profitability rating of 2 / 10.


How financially healthy is ASCENDIS PHARMA A/S - ADR?

The financial health rating of ASCENDIS PHARMA A/S - ADR (ASND) is 3 / 10.